Evidence map›Paper›PMID 42813101›Full record

ArticleOpen forum infectious diseases2026

Comparison of 6-Week Doxycycline vs 6-Week Rifampicin or 3 Weeks of Doxycycline Plus Rifampicin in the Treatment of Onchocerciasis: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial.

Sabine Specht, Ute Klarmann-Schulz, Alexander Y Debrah, Linda Batsa Debrah, Sabine Mand, Jubin Osei-Mensah, Bettina Dubben, Nana K Ayisi-Boateng, Yusif Mubarik, Yeboah Marfo-Debrekyei and 10 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sabine SpechtInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Ute Klarmann-SchulzInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0001-5826-0196
Alexander Y DebrahKumasi Center for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Linda Batsa DebrahKumasi Center for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.ORCID https://orcid.org/0000-0001-9620-3408
Sabine MandInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Jubin Osei-MensahKumasi Center for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Bettina DubbenInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Nana K Ayisi-BoatengUniversity Hospital, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Yusif MubarikKumasi Center for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Yeboah Marfo-DebrekyeiKumasi Center for Collaborative Research, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Rolf FimmersInstitute for Medical Biometry, Informatics and Epidemiology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Peter KonaduSchool of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Arcangelo RicchiutoInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Kenneth PfarrInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Barbara GruetzmacherInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Jennifer NadalInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.
Francesca TamarozziDepartment for Tropical Disease Biology, Centres for Neglected Tropical Diseases and Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Kelly JohnstonDepartment for Tropical Disease Biology, Centres for Neglected Tropical Diseases and Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Mark J TaylorDepartment for Tropical Disease Biology, Centres for Neglected Tropical Diseases and Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Achim HoeraufInstitute for Medical Microbiology, Immunology and Parasitology, University of Bonn, University Hospital Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Depletion of Methods: This randomized, placebo-controlled, double-blind, phase 2a trial with 5 treatment regimens was conducted in Ghana to determine (1) whether treatment times could be shortened as compared with 6 weeks of DOX at 200 mg daily by using a combination of DOX and rifampicin (RIF) for 3 weeks or (2) whether a dosage reduction to 6 weeks of DOX at 100 mg or a change to 6 weeks of RIF at 10 mg/kg daily would result in noninferior efficacy. Results: The primary outcome-the absence of onchocercomata with worms showing normal embryogenesis at 20 months-revealed that DOX at 200 mg or 100 mg for 6 weeks was superior to all other interventions. DOX + RIF for 3 weeks was less effective but superior to RIF alone and to placebo, suggesting that shorter regimens can be designed by combining antiwolbachials. Finally, depletion of Conclusions: Reduction of DOX from 200 to 100 mg daily facilitates implementation of this regimen, by aligning it to other regimens using 100 mg daily with a larger safety profile. The results also indicate that a combination of antiwolbachials might deliver effective regimens with shorter treatment times. Finally, the ability to predict 20-month end points of the slow-acting antiwolbachials by using

Indexed as

doxycyclineonchocerciasisrandomized controlled trialrifampicinWolbachia

Identifiers

PMID42813101
PMCPMC13622345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.